Guidelines for Finding Genetic Variants Underlying Human Disease
By Daniel MacArthur and Chris Gunter,
Genomes Unzipped
| 04. 24. 2014
New DNA sequencing technologies are rapidly transforming the diagnosis of rare genetic diseases, but they also carry a risk: by allowing us to see all of the hundreds of “interesting-looking” variants in a patient’s genome, they make it potentially easy for researchers to spin a causal narrative around genetic changes that have nothing to do with disease status. Such false positive reports can have serious consequences: incorrect diagnoses, unnecessary or ineffective treatment, and reproductive decisions (such as embryo termination) based on spurious test results. In order to minimize such outcomes the field needs to decide on clear statistical guidelines for deciding whether or not a variant is truly causally linked with disease.
In a paper in Nature this week we report the consensus statement from a workshop sponsored by the National Human Genome Research Institute, on establishing guidelines for assessing the evidence for variant causality. We argue for a careful two-stage approach to assessing evidence, taking into account the overall support for a causal role of the affected gene in the disease phenotype, followed by an assessment of the probability...
Related Articles
By Evelina Johansson Wilén, Jacobin | 01.18.2026
In her book The Argonauts, Maggie Nelson describes pregnancy as an experience marked by a peculiar duality. On the one hand, it is deeply transformative, bodily alien, sometimes almost incomprehensible to the person undergoing it. On the other hand...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By Paula Siverino Bavio, BioNews | 01.12.2026
For more than ten years, gestational surrogacy in Uruguay existed in a state of legal latency: provided for by law, carefully regulated as an exception, yet without a single birth to make it real.
That situation changed with the arrival...